Resize text 
Resize text
The ENCePP Secretariat accepts no responsibility for the content of material and/or announcements in this section, including, without limitation, any error, omission or inaccuracy therein. If the announcement provides a link to a third-party website, please see the ENCePP Linking Policy.
| Date | Subject | Links |
|---|---|---|
COVID-19 pandemic response |
||
18/05/2021 (last update: 25/08/2021) |
Background incidence rates of thromboembolic events with thrombocytopenia from 6 Member States – first report from the study on natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2 | |
04/05/2021
(last update: 25/08/2021) |
ACCESS Updated background incidence rates (AESIs and thromboembolic events) ** All ACCESS background rate data are now available on the VAC4EU dashboard ** |
|
| 19/03/2021 | ACCESS Preliminary incidence rates of embolic and thrombotic events following immunisation with COVID-19 vaccines | |
| 08/03/2021 | ACCESS Background incidence rates of adverse events of special interest (AESIs) for COVID-19 vaccines | |
For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
